ABSTRACT
Immunotherapies using cancer-testis (CT) antigens as targets represent a potentially useful treatment in patients with multiple myeloma (MM) who commonly show recurrent disease following chemotherapy. We analyzed the expression of 11 CT antigens in bone marrow samples from MM patients (N=55) and healthy donors (N=32) using RT-PCR. CT antigens were frequently expressed in MM with 56% (MAGEC2), 55% (MAGEA3), 35% (SSX1), 20% (SSX4, SSX5), 16% (SSX2), 15% (BAGE), 7% (NY-ESO-1), and 6% (ADAM2, LIPI) expressing the given antigen. Immune responses induced by alloSCT could be boosted by active CT antigenspecific immunotherapy which might help to achieve long-lasting remissions in patients with MM.
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From
INTRODUCTION
Multiple myeloma (MM) is a clonal B cell malignancy with an incidence of approximately 15,000 new cases per year in the U.S. alone and a median survival of three years. MM is characterized by an accumulation of mature plasma cells (PC) in the bone marrow (BM) leading to bone destruction and BM failure. MM remains essentially incurable by conventional anti-tumor therapy 1 . While the introduction of allogeneic stem cell transplantation (alloSCT) has resulted in higher remission rates and even cures, these therapeutic improvements have been hampered by a significantly increased treatment-related morbidity and mortality. One reason for this is that the immune responses derived from the allogeneic graft are not strictly myeloma-specific and are, therefore, associated with significant immune-mediated side effects.
It has been suggested that donor T cell-mediated graft-versus-host activities, which result from genetic disparities between donors and recipients, also include graftversus-leukemia (GvL) effects capable of controlling the underlying malignancy in the host. Clinical observations supporting this idea include decreased relapse risks in patients who develop graft-versus-host disease (GvHD) after allografting, decreased relapse rates in recipients of allogeneic compared with autologous (autoSCT) or syngeneic stem cell transplantation, induction of remission in relapsed patients following donor lymphocyte infusion, and increased relapse risks after use of T celldepleted allografts compared to unmodified preparations 2 . Minor histocompatibility and tumor-associated proteins such as differentiation antigens have been proposed as targets for GvL effects 2, 3 .
The cancer-testis (CT) class of tumor antigens is a group of currently 44 proteins, the expression of which is characteristically restricted to cancer and the human germ For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From line. Based on their immunogenicity and restricted tissue expression, CT antigens seem ideal targets for active immunotherapies 4 . However, MM is considered a malignancy generating strong systemic immunosuppression and little is known about the ability of CT antigens to induce natural immune responses in MM patients [5] [6] [7] . Furthermore, the question remains open whether CT antigens might represent targets for graft-versus-myeloma (GvM) effects following alloSCT and whether this mode of therapy might induce spontaneous CT antigen-specific immune responses.
We performed a comprehensive analysis of CT antigen expression in myeloma cell lines, in the BM of patients with MM, and in healthy BM of stem cell donors. Another major goal of our study was to investigate whether the presence of these tumor antigens in the BM of MM patients would lead to spontaneous humoral and cellular immune responses following alloSCT.
METHODS

Patients and healthy stem cell donors
A total of 106 consecutive consenting MM patients, 32 healthy stem cell donors, 40 patients with acute myeloid leukemia (AML), and 50 healthy blood donors. were included in the study. All patients were admitted for treatment of MM at the University Medical Center Hamburg-Eppendorf. The study protocol had received approval by the local ethics committee.
BM samples, sera, and myeloma cell lines
BM samples and sera from consented MM patients as well as sera from AML patients were obtained during routine diagnostic procedures. Samples obtained from consented healthy donors were part of BM donations used for alloSCT or were were collected from blood donors. MNC were isolated from BM by density gradient centrifugation and were washed twice with PBS. MNC were lysed using RLT Buffer 
Reverse transcription PCR (RT-PCR)
CT antigen expression was evaluated in 55 patients with at least 10% BM-infiltrating PC and 51 MM patients with less than 10% PC. In addition, PCR analysis was performed on 11 myeloma cell lines as well as on BM or CD34+ stem cells from 32 healthy donors. PCR primers and conditions used were those published in the CT 
Immunohistochemistry
The presence of CT antigens in actual tumor tissue was analyzed by immunohistochemistry on formalin-fixed paraffin embedded archival tissue as previously described [9] [10] [11] [12] . Monoclonal antibodies (mAbs) to the following antigens were used: mAb M3H67 (MAGEA3) 9 , 57B (MAGEA4) 10 , mAb E978 (NY-ESO-1)
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, and recently generated mAb CT10#5 (MAGEC2/CT10) 12 . All mAbs were generated by our group, except mAb 57 which was kindly provided by Dr. G. Spagnoli (Basel, Switzerland) 13 . A heat based antigen retrieval technique employing citrate buffer (mAbs 57B), EDTA (mAbs M3H67, CT10#5), or hipH solution (mAb E978) from DAKO (DAKOcytomation, Carpinteria, CA) was used before primary incubation overnight at 4 o C. As a secondary reagent a biotinylated horse-anti-mouse antibody (Vector Labs, Burlingame, CA) followed by an avidini-biotin-complex system (ABCElite, Vector Labs) was used except for mAb E978, which was detected with a polymer-based secondary reagent (Powervision system, Immunovision, Brisbane, CA). Diaminobenzidine (DAB, Biogenex, San Ramon, CA) served as chromogen and Gill's hematoxylin was used to counterstain. The immunohistochemical staining was graded based on the estimated amount of immunopositive tumor cells as follows:
focal -approximately <5%, + -5-25%, ++ >25-50%, +++ ->50-75%, ++++ ->75%.
ELISA
Sera for the analysis of serological immunoreactivity against CT antigens were available from 66 MM patients, from four of these patients' BM donors, from 40 AML 
ELISPOT assay
ELISPOT assays for the determination of antigen-specific effector T cells were performed after a single cycle of antigen-specific stimulation on day 10 of Next, we decided to investigate the expression of CT antigens frequently found in myeloma cell lines, in BM from patients with myeloma and healthy stem cell donors.
New criteria for the diagnosis of MM include the presence of at least 10% PC in the BM 18 . Therefore, we selected 55 myeloma patients who fulfilled these criteria for our study of CT antigen expression. Clinical data of all patients are listed in Table 2 . The majority of patients were male, median age was 63 years (range 36-81 years) and mean percentage of BM-infiltrating PC was 56.9. Most patients were in advanced stages with IgG kappa being the most common idiotype. At the time of inclusion into the study the majority of patients had been treated with chemotherapy alone as maximal treatment while 13 patients had received autoSCT and 7 patients had undergone alloSCT.
We found that the CT antigen most frequently expressed in PC-infiltrated BM of patients with MM was CT10/MAGEC2 followed by CT antigen MAGEA3 ( Figure 1A ).
Both genes were expressed in the BM of more than half of all myeloma patients.
Members of the SSX family of genes, including SSX1, SSX2, SSX4, and SSX5, were also commonly expressed with SSX1, as the most frequently expressed SSX gene, being present in the BM of about one third of all patients. In contrast, SSX3 was not expressed in any of the samples. CT antigen BAGE was positive in 15% of all patients. Our finding of a comparably weak expression of NY-ESO-1 in MM is in line with previous findings by others 9, [19] [20] [21] but in contrast to observations made by van Rhee et al.
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. Genes also less frequently expressed were ADAM2 and LIPI being present in fewer than 10% of all samples. It has previously been proposed that CT antigens might be expressed in healthy BM, especially in mesenchymal stem cells and in non-malignant CD34+ progenitor cells 22 . In order to find out whether CT antigen-specific immunotherapies in MM would have potential to cause significant myelotoxicity derived from BM-targeting immune responses, we examined BM samples from 26 healthy donors for the expression of the 11 CT antigens listed above. Importantly we did not detect mRNA of any CT antigen in the vast majority of all healthy BM samples. In four patients, however, we detected expression of SSX4, a finding which was confirmed by sequencing of the For personal use only. on September 24, 2017. by guest www.bloodjournal.org From PCR product (data not shown). While we did not have access to purified normal plasma cells from the majority of our healthy donors, we were able to enrich CD138+ plasma cells from at least one of these subjects. Importantly, the normal plasma cells did not express any of the CT antigens examined. Finally, We also analyzed the expression of CT antigens on CD34+ progenitor cells isolated from leukapheresis products or BM of 6 additional healthy stem cell donors. Noticeably, we did not detect expression of any of the 11 CT antigens tested in any of the CD34+ progenitor cell samples (data not shown).
We next investigated whether the expression of CT antigens in MM was related to the patients' clinical characteristics. We did not observe any association between the number of CT antigens expressed in the BM and the patient's gender, heavy or light chain isotype, or the intensity of previous treatments (Table 2) . Patients with a cytogenetic abnormality have been indicated to show an increased expression of CT antigen NY-ESO-1 5 , however, we did not observe an effect of 13q14 deletion, as determined by fluorescence in situ hybridization (FISH) 23 , on the number of CT antigens expressed. Importantly, the expression of CT antigens was also not related to the degree of PC infiltration, indicating that a minimum of 10% PC in the BM was likely to provide sufficient amounts of cDNA for CT antigen expression to be detected. In contrast, we observed a strong and positive correlation between the patient's age and the number of CT antigens expressed, a finding which is in line with observations made in some patients with solid tumors 24 . Furthermore, we observed a positive correlation between CT antigen expression and the stage of disease (Table 2 ). This finding was in line with our observation of a positive association of the number of CT antigen expressed with serum levels of We next aimed at conforming our finding of a high mRNA expression of several CT antigens in myeloma on the protein level. However, myeloma bone marrow samples suitable for immunohistochemical analysis were not available for most of our patients.
Therefore, we applied immunohistochemistry to an archived extramedullary plasmocytoma from one of our patients (BMT47). Interestingly, the tumor was strongly and homogeneously positive for NY-ESO-1, MAGEA3 and MAGEA4 with more than 75% immunopositive tumor cells for each antigen (Figures 2 A-C) . We also observed expression of CT10/MAGEC2, although this protein showed only a focal expression pattern ( Figure 2D ). Immunostaining was predominantly cytoplasmic expression for MAGE-A3 and MAGE-A4, while NY-ESO-1 was also present in the nucleus and CT10/MAGEC2 showed solely a nuclear expression (Figure 2 ).
CT antigens induce a systemic humoral immune response in MM patients following alloSCT.
Given the frequent expression of CT antigens in MM patients we analyzed whether the same patients had developed an IgG antibody response against three of these proteins (MAGEA3, SSX2, NY-ESO-1). Sera were available from a total of 66 patients of which 15 had at least 10% malignant PC in their BM and the remaining patients being in therapy-induced near-complete remission with less than 10% PC but positive immunofixation. 9 of the patients had received chemotherapy alone, 22 had received autoSCT, and 35 had received alloSCT as maximal treatment.
While none of the 50 sera from healthy controls showed any such antibody responses, we detected IgG antibodies against CT antigens in 10 of the myeloma patients' sera. One patient who had received autoSCT as maximal treatment had antibodies against NY-ESO-1 and MAGEA3. Remarkably, all of the 9 remaining antibody-positive patients belonged to the group who had undergone alloSCT ( Figure   3 ). These patients had received alloSCT between 14 and 64 months (mean 34.6 months) before their sera were first analyzed. The responses consisted of IgG antibodies against SSX2 in three cases and of responses against MAGEA3 and NY-ESO-1 in two cases, respectively. In addition, two patients showed simultaneous antibody responses against CT antigens MAGEA3 and NY-ESO-1. We were able to obtain stored sera which had been collected a few days before alloSCT from 7 of the 9 antibody-positive patients. Noticeably, none of these patients showed antibody responses against any of the CT antigens in their pre-transplant sample ( Figure 3 ).
While pre-transplant plasma samples of the patients' stem cell donors were not available to us, we were able to obtain fresh plasma samples from 4 of these patients' donors. Healthy donors generally do not show CT antigen-specific antibodies in their plasma 5, 6, 25, 26 . However, we still evaluated the patients' donors for the presence of anti-CT antigen antibodies in order to exclude the possibility that anti-CT antigen immunity had simply been transplanted into the patients. We found that all of the donors were still in complete health and none of them showed antibody responses against any of the CT antigens. Importantly, at the time their response was detectable, all myeloma patients had fully engrafted and showed >99% chimerism in their BM as analyzed by patient-specific real-time PCR, indicating that the antibody response was indeed entirely allogeneic. These findings led us to the conclusion that the allogeneic humoral immune response seemed to have developed in the patients at some point in time following alloSCT.
One of the antibody-positive patients (BMT47) had relapsed shortly before his antibody response against NY-ESO-1 was detected but the BM-infiltrating PC, while . We, therefore, performed a preliminary analysis of CT antigen-specific While we did not have access to frozen pre-BMT PBL samples from the patient's related donor, we were able to obtain fresh PBL samples from the donor at the time we conducted our analysis. In repeated experiments we did not detect any NY-ESO- In our current study we have analyzed the majority of our myeloma patients' bone marrow samples on the RNA level. Previous studies examining the expression of CT antigens in myeloma, however, indicated a strong correlation between RNA and protein expression 5, 21, 43 . Here, we provided evidence for strong protein expression of several CT antigens, including NY-ESO-1, in an extramedullary plasmocytoma of one of our patients. Interestingly, this patient also showed a strong immune response 
